Osimertinib is a highly effective third generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is the current first line standard of care for patients with metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations. Here, EGFR is linked to non-small cell lung carcinoma.